BR112022016368A2 - Anticorpos pilra e seus métodos de uso - Google Patents
Anticorpos pilra e seus métodos de usoInfo
- Publication number
- BR112022016368A2 BR112022016368A2 BR112022016368A BR112022016368A BR112022016368A2 BR 112022016368 A2 BR112022016368 A2 BR 112022016368A2 BR 112022016368 A BR112022016368 A BR 112022016368A BR 112022016368 A BR112022016368 A BR 112022016368A BR 112022016368 A2 BR112022016368 A2 BR 112022016368A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- pilra
- antigen
- binding fragments
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ANTICORPOS PILRA E SEUS MÉTODOS DE USO. A presente divulgação fornece anticorpos e seus fragmentos de ligação a antígeno que se ligam especificamente a PILRA humana e composições compreendendo estes anticorpos ou seus fragmentos de ligação a antígeno. Em um aspecto específico, os anticorpos ou seus fragmentos de ligação a antígeno que se ligam especificamente à PILRA humana bloqueiam a ligação de PILRA ao ligante e/ou diminuem a PILRA na superfície celular. Em aspectos adicionais, os anticorpos ou seus fragmentos de ligação a antígeno podem ser usados para tratar doenças ou condições associadas à disfunção das células mieloides.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062978106P | 2020-02-18 | 2020-02-18 | |
US202063075440P | 2020-09-08 | 2020-09-08 | |
PCT/US2021/018354 WO2021167964A1 (en) | 2020-02-18 | 2021-02-17 | Pilra antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016368A2 true BR112022016368A2 (pt) | 2023-01-10 |
Family
ID=74870886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016368A BR112022016368A2 (pt) | 2020-02-18 | 2021-02-17 | Anticorpos pilra e seus métodos de uso |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230220074A1 (pt) |
EP (1) | EP4106788A1 (pt) |
JP (1) | JP2023513834A (pt) |
KR (1) | KR20220143048A (pt) |
CN (1) | CN115515615A (pt) |
AU (1) | AU2021224572A1 (pt) |
BR (1) | BR112022016368A2 (pt) |
CA (1) | CA3166155A1 (pt) |
IL (1) | IL295188A (pt) |
MX (1) | MX2022010021A (pt) |
WO (1) | WO2021167964A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR128001A1 (es) * | 2021-12-17 | 2024-03-20 | Denali Therapeutics Inc | Anticuerpos anti-pilra, usos de estos y métodos y reactivos relacionados |
WO2024054848A1 (en) * | 2022-09-06 | 2024-03-14 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of phagocytosis |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
ATE243745T1 (de) | 1994-01-31 | 2003-07-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
CA2675025C (en) * | 2007-01-12 | 2012-02-21 | Osaka University | Inhibitor of herpesvirus infection, method for inhibition of herpesvirus infection, and use thereof |
US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8178094B2 (en) * | 2007-12-20 | 2012-05-15 | Schering Corporation | Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodies |
WO2011084357A1 (en) * | 2009-12-17 | 2011-07-14 | Schering Corporation | Modulation of pilr to treat immune disorders |
CN105734678B (zh) | 2010-07-16 | 2019-11-05 | 阿迪马布有限责任公司 | 合成多核苷酸文库 |
WO2012088383A2 (en) * | 2010-12-23 | 2012-06-28 | Genentech, Inc. | PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME |
SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind B7-H1 and PD-1 |
RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
WO2019126472A1 (en) * | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
-
2021
- 2021-02-17 BR BR112022016368A patent/BR112022016368A2/pt unknown
- 2021-02-17 CN CN202180017565.9A patent/CN115515615A/zh active Pending
- 2021-02-17 IL IL295188A patent/IL295188A/en unknown
- 2021-02-17 WO PCT/US2021/018354 patent/WO2021167964A1/en unknown
- 2021-02-17 EP EP21711411.5A patent/EP4106788A1/en active Pending
- 2021-02-17 AU AU2021224572A patent/AU2021224572A1/en active Pending
- 2021-02-17 CA CA3166155A patent/CA3166155A1/en active Pending
- 2021-02-17 JP JP2022549422A patent/JP2023513834A/ja active Pending
- 2021-02-17 US US17/904,513 patent/US20230220074A1/en active Pending
- 2021-02-17 KR KR1020227030339A patent/KR20220143048A/ko not_active Application Discontinuation
- 2021-02-17 MX MX2022010021A patent/MX2022010021A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230220074A1 (en) | 2023-07-13 |
AU2021224572A1 (en) | 2022-08-25 |
KR20220143048A (ko) | 2022-10-24 |
JP2023513834A (ja) | 2023-04-03 |
WO2021167964A1 (en) | 2021-08-26 |
EP4106788A1 (en) | 2022-12-28 |
MX2022010021A (es) | 2022-11-09 |
CA3166155A1 (en) | 2021-08-26 |
IL295188A (en) | 2022-09-01 |
CN115515615A (zh) | 2022-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022016368A2 (pt) | Anticorpos pilra e seus métodos de uso | |
BR112020012647A8 (pt) | Anticorpos anti-tígitos e seu uso como agentes terapêu-ticos e diagnósticos | |
BR112019000436A2 (pt) | anticorpos anti-pd-1, método de produção e método de uso dos mesmos | |
BR112016003369A2 (pt) | diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma | |
BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
BR112017019785A2 (pt) | anticorpos terapêuticos e seus usos | |
BR112018013653A2 (pt) | anticorpos anti-pd-1 | |
BR112021009275A2 (pt) | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. | |
CL2008001741A1 (es) | Anticuerpo quimerico o humanizado o fragmento de los mismos que se unen especificamente a por lo menos un epitope en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados con la formacion de placas amiloides. | |
BR112016011401A2 (pt) | moduladores de aplnr e utilizações dos mesmos | |
BR112015032690A2 (pt) | uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases | |
PE20170764A1 (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1) | |
BR112017004510A8 (pt) | anticorpos monoclonais isolados; anticorpos monoclonais ou fragmentos de ligação a antígenos do mesmo; composição; moléculas polinucleotídicas isoladas; polipeptídeo recombinante; polipeptídeos; célula hospedeira; método de fabricação de um anticorpo; uso de um agente para o tratamento de câncer em um paciente; usos de anticorpo monoclonal ou fragmento de ligação a antígenos do mesmo para o tratamento de um sujeito que sofre de um câncer; uso de anticorpo monoclonal para o tratamento de um sujeito que sofre de um câncer; composição compreendendo um anticorpo de ligação a agr2; composição compreendendo um anticorpo de ligação a c4.4a; composição compreendendo um anticorpo de ligação a agr2 e um anticorpo de ligação a c4.4a; composição compreendendo um anticorpo; uso de um anticorpo de ligação a agr2; uso de um anticorpo de ligação a c4.4a; uso de um anticorpo; e kit compreendendo um anticorpo | |
UY37757A (es) | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante | |
BR112022013756A2 (pt) | Anticorpos anti-trem2 e métodos de uso dos mesmos | |
BR112022011570A2 (pt) | Anticorpos anti-mertk e métodos de uso dos mesmos | |
BR112021025077A2 (pt) | Anticorpos anti-sortilina para uso em terapia | |
BR112022024262A2 (pt) | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april | |
BR112022012093A2 (pt) | Anticorpos contra integrina alfa 11 beta 1 | |
BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
BR112020016330A8 (pt) | Receptores de células t específicas a ciclina a1 e usos dos mesmos | |
CO2023010206A2 (es) | Conjugados de anticuerpo dirigido a b7-h4 y fármaco, y métodos de uso de los mismos | |
BR112017022205A2 (pt) | anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada | |
CO2023001559A2 (es) | Anticuerpos fgfr3 y métodos de uso | |
AR117735A1 (es) | ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO |